Tao Li is a strategic scientific leader with over 25 years of experience in biologics, vaccines, and advanced manufacturing. They served as Senior Director at Sanaria from 2006 to 2022 and held roles as Program Director III at ABL from 2022 to 2024 and Director at US Pharmacopeia since 2024. Tao completed a Ph.D. at the Changchun Institute of Applied Chemistry and a BS at Jilin University, along with additional doctoral studies at Charles University. Their prior positions include Research Fellow at Harvard Medical School/Joslin Diabetes Center and Visiting Fellow at the National Institute of Child and Human Development.
This person is not in the org chart
This person is not in any teams
This person is not in any offices